02 Jul 2015

Rocephin vials (Ceftriaxone) - United Kingdom

Rocephin vials

Last Updated on 02 Jul 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Rocephin vials Indication

Rocephin is indicated for the treatment of the following infections in adults and children including term neonates (from birth):

Bacterial Meningitis

Community acquired pneumonia

Hospital acquired pneumonia

Acute otitis media

Intra-abdominal infections

Complicated urinary tract infections (including pyelonephritis)

Infections of bones and joints

Complicated skin and soft tissue infections



Bacterial endocarditis

Rocephin may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults

For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections

In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection

In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Rocephin should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.


Rocephin vials Generic Name




Summary Product Characteristics (SPCs) Links
SPC - Rocephin 250mg, 1g and 2g vials (external site)

Related Learning Zones

Anti-Coagulation Video Channel

Anti-Coagulation Video Channel

The Anti-Coagulation Video Channel is regularly updated with expert videos discussing how to prevent stroke and systemic embolism in non-valvular atrial fibrillation (AF) patients and how to prevent and treat venous thromboembolism (VTE). This free resource is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with AF or VTE.

This resource has been developed in collaboration with Boehringer Ingelheim.

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Rocephin vials Marketing Information

Rocephin vials Generic Name
Marketing Company
Roche Products Limited
Drug Type
Date of Issue, Marketing Authority 23/10/2003

Related Drugs - Infectious Diseases

Back to top